Jamie B Spangler
Overview
Explore the profile of Jamie B Spangler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
1102
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rana J, VanDyke D, Munoz-Melero M, Fabilane C, Thirumurugan S, Arisa S, et al.
J Thromb Haemost
. 2025 Mar;
PMID: 40056981
Background: The development of inhibitory antibodies (inhibitors) is a serious complication in the treatment of hemophilia A with clotting factor VIII (FVIII) replacement therapy. Inhibitor formation critically depends on T...
2.
Kim S, Lee H, Gingras A, Ley K, Spangler J, Ginsberg M
bioRxiv
. 2025 Feb;
PMID: 39975281
IL-2, a central regulator of immune function, binds to its receptor subunit CD25 (IL-2Rα), promoting IL-2 interaction with β and γ subunits to trigger the canonical IL-2 signaling pathway. An...
3.
Rahnama R, Kizerwetter M, Yang H, Christodoulou I, Guaraca C, Holl N, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39915004
Background: Natural Killer (NK) cells have intrinsic anticancer activity that can be redirected toward acute myeloid leukemia (AML) with chimeric antigen receptor (CAR) engineering. Here, we study the functional consequences...
4.
Sehgal P, Naqvi A, Higgins M, Liu J, Harvey K, Jarroux J, et al.
bioRxiv
. 2025 Jan;
PMID: 39868324
Statement Of Significance: Existing targets for chimeric antigen receptors (CAR)-armed T cells are often shared by CNS tumors and normal tissues, creating the potential for on-target/off-tumor toxicities. Here we demonstrate...
5.
Ariail E, Garcia Espinoza N, Stephenson A, Spangler J
Cell Syst
. 2024 Dec;
15(12):1198-1208.
PMID: 39701036
T cells are key mediators of the adaptive immune response, playing both direct and supporting roles in the destruction of foreign pathogenic threats as well as pathologically transformed host cells....
6.
Woodward C, Solieva S, Hwang D, De Paula V, Fabilane C, Young M, et al.
J Mol Biol
. 2024 Dec;
437(2):168892.
PMID: 39662679
Human interleukin-2 (IL-2) is a crucial cytokine for T cell regulation, with therapeutic potential in cancer and autoimmune diseases. However, IL-2's pleiotropic effects across different immune cell types often lead...
7.
Bernstein Z, Gierke T, Dammen-Brower K, Tzeng S, Zhu S, Chen S, et al.
J Biol Chem
. 2024 Nov;
300(12):108005.
PMID: 39551135
Molecular conjugation to antibodies has emerged as a growing strategy to combine the mechanistic activities of the attached molecule with the specificity of antibodies. A variety of technologies have been...
8.
Woodward C, Solieva S, Hwang D, De Paula V, Fabilane C, Young M, et al.
bioRxiv
. 2024 Oct;
PMID: 39416199
Highlights: NMR and molecular dynamics simulations revealed distinct conformational dynamics and allosteric networks in computationally re-designed IL-2 superkines compared to wild-type IL-2, despite their similar crystal structures.The superkines S1 and...
9.
An X, Paoloni J, Oh Y, Spangler J
Trends Cancer
. 2024 Oct;
10(12):1131-1146.
PMID: 39389907
Growth factors signal through engagement and activation of their respective cell surface receptors to choreograph an array of cellular functions, including proliferation, growth, repair, migration, differentiation, and survival. Because of...
10.
Huang B, Abedi M, Ahn G, Coventry B, Sappington I, Tang C, et al.
Nature
. 2024 Sep;
638(8051):796-804.
PMID: 39322662
Endocytosis and lysosomal trafficking of cell surface receptors can be triggered by endogenous ligands. Therapeutic approaches such as lysosome-targeting chimaeras (LYTACs) and cytokine receptor-targeting chimeras (KineTACs) have used this to...